The goal of the Academic Drug Discovery Consortium (ADDC) is to build a collaborative network among the growing number of university-led drug discovery centers and programs. With this interactive website, we aim to allow scientists to exchange technical expertise on drug discovery and development strategies as well as form partnerships with each other, biopharma companies, and drug discovery-focused contract service organizations and consultants. The website will also serve as a repository for drug discovery events, educational material, job postings, and partnership opportunities. It is with the active participation of each ADDC member that this website will become a valuable tool for every scientist working in the drug discovery arena. In addition, involvement of our members will enable the ADDC to effectively advocate to the NIH and other funding agencies to increase the awareness of the growing number of academic drug discovery scientists and their success as well as their needs.
Our centre combines strong expertises in RNAi based target discovery, modelling/virtual screening and medicinal chemistry. New therapeutic targets (main programs: cancer and regenerative medicine) are functionally identified via in vitro or in vivo s...View all
Johns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted main...View all